Completed NA INTERVENTIONAL 2-arm NCT04446429

Anti-Androgen Treatment for COVID-19

Sponsor: Applied Biology, Inc.

Conditions Androgenetic Alopecia Benign Prostatic Hyperplasia COVID-19 Prostate Cancer SARS (Severe Acute Respiratory Syndrome) SARS-CoV2

Interventions Proxalutamide Standard of Care

Updated 9 times since 2020 Last updated: Dec 8, 2021 Started: Oct 21, 2020 Primary completion: Dec 24, 2020 Completion: Jan 21, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Androgenetic Alopecia and Benign Prostatic Hyperplasia and is currently completed. Applied Biology, Inc. leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2022 — Jul 2024 [monthly]

Completed NA
Sep 2021 — Jan 2022 [monthly]

Completed NA

▶ Show 4 earlier versions

Mar 2021 — Sep 2021 [monthly]

Completed NA

Status: Recruiting → Completed
Jan 2021 — Mar 2021 [monthly]

Recruiting NA
Aug 2020 — Jan 2021 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Jul 2020 — Aug 2020 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Applied Biology, Inc.

Data source: Applied Biology, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brasília, Brazil